| A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy (NCT05592990) | Novartis Pharmaceuticals | 2023-06-14 |
| A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea (NCT05703516) | Novartis Pharmaceuticals | 2023-06-12 |
| Epidemiology and Treatment of HR+/HER2- Breast Cancer in England (NCT07498413) | Novartis Pharmaceuticals | 2023-06-08 |
| A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis (NCT07027163) | Novartis Pharmaceuticals | 2023-06-01 |
| Safety and Efficacy of RHH646 for Knee Osteoarthritis (NCT05816395) | Novartis Pharmaceuticals | 2023-05-31 |
| Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy (NCT06692803) | Novartis Pharmaceuticals | 2023-05-23 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC (NCT05670106) | Novartis Pharmaceuticals | 2023-05-16 |
| Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure (NCT05870709) | Novartis Pharmaceuticals | 2023-05-15 |
| A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma (NCT05562466) | Novartis Pharmaceuticals | 2023-05-11 |
| Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases (NCT05552469) | Novartis Pharmaceuticals | 2023-05-08 |
| A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (NCT05658003) | Novartis Pharmaceuticals | 2023-05-05 |
| A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) (NCT05252585) | Novartis Pharmaceuticals | 2023-05-01 |
| Long-term Extension Study of Ligelizumab in Food Allergy (NCT05678959) | Novartis Pharmaceuticals | 2023-04-27 |
| Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) (NCT05624749) | Novartis Pharmaceuticals | 2023-04-21 |
| A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks. (NCT05795153) | Novartis Pharmaceuticals | 2023-04-05 |
| Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care (NCT06004453) | Novartis Pharmaceuticals | 2023-04-03 |
| A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in Germany (NCT07653126) | Novartis Pharmaceuticals | 2023-04-03 |
| A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life (NCT06923124) | Novartis Pharmaceuticals | 2023-03-30 |
| Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants (NCT05764265) | Novartis Pharmaceuticals | 2023-03-27 |
| Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) (NCT05767034) | Novartis Pharmaceuticals | 2023-03-22 |
| Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. (NCT05763875) | Novartis Pharmaceuticals | 2023-03-15 |
| Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD) (NCT05454410) | Novartis Pharmaceuticals | 2023-03-13 |
| A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. (NCT05739383) | Novartis Pharmaceuticals | 2023-03-09 |
| A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects (NCT06905327) | Novartis Pharmaceuticals | 2023-03-08 |
| A Study to Evaluate the Impact of Long-term Digital Education vs Standard of Care on LDL-C Levels in Post Myocardial Infarction Patients (NCT06548555) | Novartis Pharmaceuticals | 2023-03-08 |
| A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery. (NCT05524051) | Novartis Pharmaceuticals | 2023-03-03 |
| Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera (NCT05548062) | Novartis Pharmaceuticals | 2023-03-02 |
| Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) (NCT05639114) | Novartis Pharmaceuticals | 2023-03-02 |
| A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients (NCT07039383) | Novartis Pharmaceuticals | 2023-03-01 |
| A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension (NCT06683768) | Novartis Pharmaceuticals | 2023-02-28 |
| An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus (NCT05798117) | Novartis Pharmaceuticals | 2023-02-28 |
| Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. (NCT05201066) | Novartis Pharmaceuticals | 2023-02-28 |
| Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants (NCT05469360) | Novartis Pharmaceuticals | 2023-02-23 |
| A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant (NCT05447663) | Novartis Pharmaceuticals | 2023-02-23 |
| Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies (NCT05682378) | Novartis Pharmaceuticals | 2023-02-10 |
| Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (NCT05666804) | Novartis Pharmaceuticals | 2023-02-06 |
| Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension (NCT06604897) | Novartis Pharmaceuticals | 2023-01-31 |
| Patterns of Inclisiran Use in the Real World: An Analysis of US Databases (NCT07023445) | Novartis Pharmaceuticals | 2023-01-20 |
| A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China (NCT05576792) | Novartis Pharmaceuticals | 2023-01-13 |
| Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps (NCT05626257) | Novartis Pharmaceuticals | 2023-01-12 |
| Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam (NCT05386680) | Novartis Pharmaceuticals | 2023-01-12 |
| An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the Brain (NCT05666687) | Novartis Pharmaceuticals | 2023-01-11 |
| The 'Wearing Off' Effect of DMT (NCT05627271) | Novartis Pharmaceuticals | 2023-01-10 |
| Kesimpta (Ofatumumab) Pregnancy Registry (NCT05634967) | Novartis Pharmaceuticals | 2023-01-05 |
| A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia (NCT05648968) | Novartis Pharmaceuticals | 2022-12-30 |
| Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors (NCT05429502) | Novartis Pharmaceuticals | 2022-12-27 |
| A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib (NCT07363434) | Novartis Pharmaceuticals | 2022-12-21 |
| Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials (NCT05335876) | Novartis Pharmaceuticals | 2022-12-19 |
| Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France (NCT05697146) | Novartis Pharmaceuticals | 2022-12-13 |
| An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib (NCT05513001) | Novartis Pharmaceuticals | 2022-12-09 |
| Characterizing the Use of Ofatumumab in a Real World Setting (NCT05090033) | Novartis Pharmaceuticals | 2022-12-08 |
| Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. (NCT05445843) | Novartis Pharmaceuticals | 2022-12-06 |
| Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy (NCT05569174) | Novartis Pharmaceuticals | 2022-12-02 |
| Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment (NCT05599932) | Novartis Pharmaceuticals | 2022-12-02 |
| Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury (NCT05507437) | Novartis Pharmaceuticals | 2022-11-22 |
| A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (NCT05456191) | Novartis Pharmaceuticals | 2022-11-21 |
| Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry (NCT06172426) | Novartis Pharmaceuticals | 2022-11-17 |
| Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (NCT05384587) | Novartis Pharmaceuticals | 2022-11-11 |
| To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF (NCT05497284) | Novartis Pharmaceuticals | 2022-11-10 |
| A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA (NCT05462990) | Novartis Pharmaceuticals | 2022-11-09 |
| An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients. (NCT05562934) | Novartis Pharmaceuticals | 2022-11-08 |
| A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants (NCT05753592) | Novartis Pharmaceuticals | 2022-10-31 |
| Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies (NCT05566756) | Novartis Pharmaceuticals | 2022-10-28 |
| A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (NCT05544929) | Novartis Pharmaceuticals | 2022-10-26 |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (NCT05358249) | Novartis Pharmaceuticals | 2022-10-24 |
| A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis (ASAP Study) (NCT05758402) | Novartis Pharmaceuticals | 2022-10-20 |
| Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts (NCT05432388) | Novartis Pharmaceuticals | 2022-10-12 |
| Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer (NCT05275868) | Novartis Pharmaceuticals | 2022-10-05 |
| Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States (NCT06161051) | Novartis Pharmaceuticals | 2022-10-03 |
| Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (NCT05397496) | Novartis Pharmaceuticals | 2022-10-03 |
| Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission (NCT05380453) | Novartis Pharmaceuticals | 2022-09-29 |
| Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma (NCT06251934) | Novartis Pharmaceuticals | 2022-09-28 |
| Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database (NCT06148493) | Novartis Pharmaceuticals | 2022-09-20 |
| Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD (NCT05399992) | Novartis Pharmaceuticals | 2022-09-12 |
| A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China (NCT05388916) | Novartis Pharmaceuticals | 2022-09-08 |
| A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD) (NCT06699914) | Novartis Pharmaceuticals | 2022-09-06 |
| Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. (NCT05110196) | Novartis Pharmaceuticals | 2022-09-03 |
| Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection (NCT05526729) | Novartis Pharmaceuticals | 2022-09-02 |
| Asciminib Roll-over Study (NCT04877522) | Novartis Pharmaceuticals | 2022-08-30 |
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma (NCT05222529) | Novartis Pharmaceuticals | 2022-08-29 |
| Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis (NCT05232864) | Novartis Pharmaceuticals | 2022-08-22 |
| A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany (NCT05305664) | Novartis Pharmaceuticals | 2022-08-19 |
| Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA). (NCT05206591) | Novartis Pharmaceuticals | 2022-08-16 |
| Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study. (NCT06271369) | Novartis Pharmaceuticals | 2022-08-11 |
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V (NCT05268289) | Novartis Pharmaceuticals | 2022-08-10 |
| Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC (NCT04926831) | Novartis Pharmaceuticals | 2022-08-10 |
| Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy (NCT06619704) | Novartis Pharmaceuticals | 2022-08-10 |
| Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment (NCT05631795) | Novartis Pharmaceuticals | 2022-08-09 |
| A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan (NCT07649252) | Novartis Pharmaceuticals | 2022-08-01 |
| Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome (NCT05350072) | Novartis Pharmaceuticals | 2022-07-28 |
| Secondary Use of PARALLEL-HF Data (NCT07527767) | Novartis Pharmaceuticals | 2022-07-27 |
| Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments. (NCT05124925) | Novartis Pharmaceuticals | 2022-07-27 |
| Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf (NCT05266469) | Novartis Pharmaceuticals | 2022-07-26 |
| Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China (NCT05199571) | Novartis Pharmaceuticals | 2022-07-22 |
| Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis (NCT05126277) | Novartis Pharmaceuticals | 2022-07-14 |
| A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab (NCT05142696) | Novartis Pharmaceuticals | 2022-07-13 |
| Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events (NCT05360446) | Novartis Pharmaceuticals | 2022-07-08 |
| Roll-over Study to Allow Continued Access to Ribociclib (NCT05161195) | Novartis Pharmaceuticals | 2022-07-07 |
| A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan (NCT07150793) | Novartis Pharmaceuticals | 2022-07-05 |
| A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (NCT05415072) | Novartis Pharmaceuticals | 2022-07-04 |